Best of the Blog: IN VIVO, June 2008

In May, Windhover's editorial staff posted 35 articles to the blog, covering biopharma, device and diagnostics R&D, business development, regulatory and commercial news. Here are a few of our favorite posts that didn't make it into stories covered elsewhere in this month's magazine: Changing of the Change Agents: Exit Wyeth's Ruffolo, Enter Orbimed's Dolsten; Cimzia Launch: Nothing Simple About It; Lundbeck Thanks Myriad For the Memories; Takeda's Millions Buy a Lot of Beer.

Best of the Blog is a monthly column highlighting the best of our free online content at www.windhover.com/blog. In May, Windhover’s editorial staff posted 35 articles to the site, covering biopharma, device and diagnostics R&D, business development, regulatory and commercial news. Last month we took an in-depth look at the FDA advisory committee review of Cephalon’s Fentora, interviewed some FDA brass, and analyzed the month’s important deals, from Takeda’s spree to BMS’ string of pearls. Here are a few of our favorite blog posts for stories not covered elsewhere in this month’s IN VIVO.

(May 1.) We just heard the news that Bob Ruffolo, Wyeth’s R&D boss, is retiring.

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on In Vivo for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Archive

More from In Vivo

Deals Shaping The Industry, May 2025

 
• By 

An interactive look at pharma, medtech and diagnostics deals made during May 2025. Data courtesy of Biomedtracker.

Podcast: Flagship’s Vision To Predict And Prevent Illness, With Raj Panjabi

 
• By 

Flagship Pioneering senior partner Raj Panjabi discusses shifting health care from reactive treatment to AI-powered prediction and prevention of disease before symptoms emerge.

Rising Leaders 2025: Namrata Saroj On The Importance Of Authenticity In Ophthalmology

 

Namrata Saroj, chief business officer of Ocular Therapeutix, is highly respected in the retina community for her contributions to drug development. She talked to In Vivo about her journey in ophthalmology, leadership philosophy and the importance of authenticity in a close-knit specialty.